Skip to main content
. 2022 Nov 16;29(11):8794–8801. doi: 10.3390/curroncol29110691

Table 1.

Summarized clinical characteristics of the 25,103 patients included in this study.

ADC SCC ASC SGC SC NSCLC, NOS SCLC LCNEC Total
N-MAC MAC
Total, n (%) 12,455 (49.6) 421 (1.7) 6655 (26.5) 126 (0.5) 785 (3.1) 225 (0.9) 1713 (6.8) 2373 (9.5) 350 (1.4) 25,103 (100)
Age, median (IQR) 61 (53–69) 62 (54–70) 66 (60–72) 62 (55–68) 59 (50–67) 64 (54–70) 65 (56–71) 65 (58–70) 65 (60–71) 63 (56–70)
Sex, n (%)
  Male 6849 (55.0) 196 (46.6) 6162 (92.6) 92 (73.0) 399 (50.8) 177 (78.7) 1344 (78.5) 2059 (86.8) 310 (88.6) 17,594 (70.1)
  Female 5606 (45.0) 225 (53.4) 493 (7.4) 34 (27.0) 386 (49.2) 48 (21.3) 369 (21.5) 314 (13.2) 40 (11.4) 7515 (29.9)
Metastasis, n (%)
  Absent 7363 (59.1) 363 (86.2) 5212 (78.3) 81 (64.3) 643 (81.9) 135 (60.0) 821 (47.9) 1145 (48.3) 187 (53.4) 15,950 (63.5)
  Present 5092 (40.9) 58 (13.8) 1443 (21.7) 45 (35.7) 142 (18.1) 90 (40.0) 892 (52.1) 1228 (51.7) 163 (46.6) 9153 (36.5)
Number of organs with metastasis, n (%)
  1–3 4786 (94.0) 56 (96.6) 1384 (95.9) 40 (88.9) 127 (89.4) 81 (90.0) 824 (92.4) 1163 (94.7) 146 (89.6) 8607 (94.0)
  4–6 301 (5.9) 2 (3.4) 59 (4.1) 4 (8.9) 13 (9.2) 8 (8.9) 64 (7.2) 64 (5.2) 17 (10.4) 532 (5.8)
  7+ 5 (0.1) 0 (0) 0 (0) 1 (2.2) 2 (1.4) 1 (1.1) 4 (0.4) 1 (0.1) 0 (0) 14 (0.2)
History of another malignancy
  No 11,279 (90.6) 347 (82.4) 5936 (89.2) 117 (92.9) 662 (84.3) 198 (88.0) 1635 (95.4) 2251 (94.9) 308 (88.0) 22,733 (90.6)
  Yes 1176 (9.4) 74 (17.6) 719 (10.8) 9 (7.1) 123 (15.7) 27 (12.0) 78 (4.6) 122 (5.1) 42 (12.0) 2370 (9.4)

ADC, adenocarcinoma; N-MAC, non-mucinous adenocarcinoma; MAC, mucinous adenocarcinoma; SCC, squamous cell carcinoma; ASC, adenosquamous carcinoma; SGC, salivary-gland type carcinoma; SC, sarcomatoid carcinoma; NSCLC, non-small cell lung cancer; NOS, not otherwise specified; SCLC, small cell lung cancer; LCNEC, large cell neuroendocrine carcinoma; IQR, interquartile range; LCa, lung cancer; Dx, diagnosis.